Anruixi (Zuberitamab) – DLBCL | HongKong DengYue Medicine

Anruixi Application Scope

Anruixi is a chimeric anti‑CD20 monoclonal antibody (zuberitamab) approved in China for CD20⁺ diffuse large B‑cell lymphoma (DLBCL).

Characteristics

• Ingredients: Zuberitamab

• Properties:

  • Targets the CD20 antigen on B cells

  • Induces B‑cell depletion via ADCC and CDC mechanisms

  • Class I innovative biologic developed domestically in China

• Packaging Specification: Supplied as a solution for injection in prefilled vials

• Storage: Store at 2–8 °C; do not freeze

• Expiry Date: As indicated on the packaging

• Executive Standard: Meets China NMPA Class I innovator biologic standards

• Approval Number: NMPA approval number for CD20⁺ DLBCL indication (May 2023)

• Date of Revision:

  • Most label updates in late 202,3

  • As it was included in the National Medical Insurance List

• Manufacturer: BioRay Pharmaceutical Co., Ltd. (China)

Guidelines for the Use of Anruixi

• Dosage and Administration:

  • Administered intravenously in combination with CHOP chemotherapy for CD20⁺ DLBCL

  • Specific dosing per label and institutional protocol

• Adverse Reactions:

  • Infusion reactions, neutropenia, infections

  • The safety profile is comparable to rituximab

• Contraindications: Known hypersensitivity to zuberitamab or murine proteins

• Precautions:

  • Pre‑medication is advised to reduce infusion reactions

  • Monitor blood counts, infection signs, and infusion tolerance

Anruixi Interactions

• Drug Interactions:

  • No major interactions reported

  • Observe for additive immunosuppression with chemo agents

Note:

• If there is a new packaging for the drug, the new packaging shall prevail. The above information is sourced from DengYue Medicine.
• It is only for internal discussion among medical staff and does not serve as a basis for medication. For specific medication guidelines, please consult the attending physician.